In 2013, the first review article recommending the introduction of the sulfoximine group to the medicinal chemist's toolbox was published.Sulfoximines, the mono-aza analogs of sulfones, by then had received little interest in drug discovery, despite their very interesting properties.However, interest in sulfoximines has increased substantially in recent years, which is exemplified by an ever-increasing number of scientific articles and life science patent applications, as well as com. available sulfoximine building blocks.Moreover, the selection of novel sulfoximine clin. candidates (e.g.VIP152, AZD6738, IM-250) serves to highlight the increased acceptance of this formerly neglected functional group by the drug discovery community.This presentation highlights emerging trends and opportunities for drug designers for the utilization of the versatile sulfoximine group in medicinal chem., such as in the construction of complex mols., proteolysis targeting chimeras (PROTACs), antibody-drug conjugates (ADCs), cyclic peptides and novel warheads for covalent inhibition.